When it comes to gene editing, we’ve already spoken about stocks like CRISPR Therapeutics (CRSP), which has been incredibly explosive. While we still like CRSP, another one that’s starting to push higher is Intellia Therapeutics (NLTA).

Most recently, NTLA announced the European Commission (EC) granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE, as noted in a company press release.

If you aren't looking at this number every time you trade an option, you are leaving money on the table. Click here to see what this critical factor is.

However, its most powerful near-term catalysts are its competitors’ key catalyst dates – which we believe NTLA can piggyback on.

For one, CRSP has its US FDA PDUFA date of December 9 coming up. That’s where we’ll hear if the US FDA will approve its treatment for sickle cell.

Two, Editas Medicine (EDIT) “will share clinical data updates from the RUBY trial for severe sickle cell disease (SCD) and the EdiTHAL trial for transfusion-dependent beta thalassemia (TDT) in a company-sponsored webinar and in a poster at the American Society of Hematology (ASH) annual meeting on Monday, December 11.”


Ian Cooper